Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Haploidentical Hematopoietic Stem Cell Transplantation for Participants With Germline RUNX1 Associated Hematologic Malignancies

NCT07524530 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT07524530
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07524530 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Haploidentical Hematopoietic Stem Cell Transplantation for Participants With Germline RUNX1 Associated Hematologic Malignancies
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2
Overall status
Not yet recruiting
Start date
October 19, 2026
Completion date
June 1, 2036
Enrollment
102 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

core binding factor alpha subunits, hematologic neoplasms, leukemia, lymphoma